Semaglutide, developed by Novo Nordisk, is an analogue of the human glucagon-like peptide (GLP-1) hormone, and induces weight loss by reducing hunger, increasing feelings of fullness and helping people eat less.
An oral presentation of data from this trial investigating the safety and efficacy of semaglutide as a potential treatment for adults with obesity took place at the Endocrine Society’s annual meeting in Chicago (ENDO).
Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in a phase 2 trial, significantly more than those treated with placebo who lost 2.3% of their body weight.
The results were from a phase 2, 52-week double blind dose-ranging study of once-daily semaglutide versus placebo and liraglutide 3 mg as active control. All trial participants also received dietary and physical exercise counselling.
Novo Nordisk plans to initiate a phase 3 clinical development programme, STEP (Semaglutide Treatment Effect in People with obesity), with once-weekly subcutaneous semaglutide in obesity in 2018.